Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder

Phase 3 Program Can Advance and the Company Plans to Initiate Registration Studies in the Fourth Quarter of 2020 

See more here